Overview

Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC

Status:
RECRUITING

Trial end date:
2027-07-01

Target enrollment:

Participant gender:

Summary

This is a Phase I/II open-label, efficacy and safety study of bicalutamide in combination with sunitinib in patients with advanced renal cell carcinoma (RCC) who have been treated with a receptor tyrosine kinase inhibitor (RTKI) and experienced disease progression.

Phase:

PHASE1

Details

Lead Sponsor:

State University of New York at Buffalo

Treatments:

bicalutamide
Sunitinib